 Mass High Tech | Biogen Idec's CEO Discusses Q1 2012 Results - Earnings Call Transcript Seeking Alpha At the American Academy of Neurology meeting lastly, our pipeline was the subject of 49 platform presentations and posters, including new data for TYSABRI, BG-12, FAMPYRA, daclizumab, dexpramipexole and Anti-Lingo. We were able to present the full data ... Biogen Idec Increases Revenue 7% to $1.3 Billion in the First Quarter |
